BioSpace News Archive

TFF Pharmaceuticals, Inc. today announced that company management will be participating in the 2023 Benchmark Discovery One-on-One Investor Conference being held December 7, 2023 at the New York Athletic Club in New York City.

Neumora Therapeutics, Inc. today announced the initiation of a Phase 1 single ascending dose / multiple ascending dose study evaluating NMRA-266 in healthy adult participants.

Xenon Pharmaceuticals Inc. today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder, or MDD.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, and Kim Kelderman , Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST.

RTI Surgical, a leading global medical device organization, announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for a clinical study designed to confirm the safety and effectiveness of Cortiva ® Allograft Dermis in implant-based breast reconstruction.

Alterity Therapeutics today announced a poster presentation from the Company’s Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural History Study at the recent 34th International Symposium on the Autonomic Nervous System (AAS).

AWAK Technologies today announced that its kidney disease progression prediction (KDPP) Artificial Intelligence (AI) model for CKD patient care has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).

Halia Therapeutics today announced that it will be presenting at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place December 9 – 12, 2023, in San Diego, California, and virtually.

Innate Pharma SA announced that it will host a virtual KOL event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma and peripheral T cell lymphoma, on Tuesday, December 12, 2023, at 7:00AM PST.

Hemogenyx Pharmaceuticals plc is pleased to announce that its Chimeric Bait Receptor platform can potentially be used in the treatment of cancers, in addition to the viral diseases extensively reported by the Company to date.